Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
RESEARCH TOOLSreports
Holding BLRX?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.19Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -67.99%
|Next Earnings Date:Aug 13, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted a major licensing agreement and debt restructuring, which position BioLineRx favorably for future growth and stability. However, challenges remain, including a net loss, closure of U.S. operations, and uncertainty around China market revenues.Company Guidance
During the BioLineRx third quarter 2024 financial results conference call, the company provided guidance on several key metrics. The recent license agreement with Ayrmid Limited for motixafortide, branded as APHEXDA, included a $10 million upfront payment, potential commercial milestones of up to $87 million, and royalties ranging from 18% to 23%. Additionally, a $9 million equity investment from Highbridge Capital was received. The company plans to cut its annual cash burn by over 70% starting January 1, 2025, with a cash runway extending into 2026. BioLineRx achieved a 10% market share in the U.S. CXCR4 inhibitor market by the end of Q3 2024, with APHEXDA being placed on formularies covering over 40% of transplant procedures. They also reported a net revenue of $1.7 million from APHEXDA product sales in the U.S. for the quarter.Significant Licensing Agreement with Ayrmid Limited
BioLineRx executed an exclusive license agreement with Ayrmid Limited for motixafortide, securing a $10 million upfront payment, $87 million in potential commercial milestones, and royalties between 18% and 23%.
Equity Investment and Debt Restructuring
BioLineRx received a $9 million equity investment from Highbridge Capital, which along with the licensing agreement, enabled repayment of $16.5 million of debt and restructuring of remaining debt under favorable terms with BlackRock.
APHEXDA Market Penetration
APHEXDA achieved formulary placement at institutions managing over 40% of transplant procedures and reached a 10% market share of total CXCR4 inhibitor usage in the U.S.
Strong Financial Performance
Reported $4.9 million in total revenue for Q3 2024, marking an increase from no recorded revenue in Q3 2023.
Cost Reduction and Cash Runway
BioLineRx's annual cash burn is expected to reduce by over 70% starting January 1, 2025, with a cash runway extending into 2026.
---
BLRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 25, 2024 | $11.12 | $10.87 | -2.25% |
| Aug 15, 2024 | $31.00 | $27.13 | -12.48% |
| May 28, 2024 | $27.40 | $28.76 | +4.96% |
| Mar 26, 2024 | $52.00 | $41.20 | -20.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bioline RX Ltd Sponsored ADR (BLRX) report earnings?
Bioline RX Ltd Sponsored ADR (BLRX) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Bioline RX Ltd Sponsored ADR (BLRX) earnings time?
Bioline RX Ltd Sponsored ADR (BLRX) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLRX EPS forecast?
BLRX EPS forecast for the fiscal quarter 2024 (Q4) is -0.02.
---